All
Team
Company
Patients
Physicians
Hospital
Partners
Mission
Innovation Details
Investor Info
Due Diligence Docs
Supporters
Comments
Updates
About our project
The problem we solve: Close to 80 million are threatened with irreversible loss due to glaucoma. Important disease parameters can momentarily only gathered at infrequent eye center visits. Disease progression, therapeutic response and patient compliance between office visits are currently unknown, resulting in progressive vision loss.
About our solution:
Implandata's EYEMATE system collects important disease parameters via biosensors and mobile data collection solutions with the patient under normal life conditions, enabling disease monitoring and timely disease management. The EYEMATE system provides remote patient care and data-driven therapy guidance.
Progress to
date:
The EYEMATE system is the first CE marked solution for remote monitoring and management of glaucoma patients. Safety, utility and efficacy have been extensively demonstrated in clinical studies and post-market surveillance.
With CE mark, the EYEMATE can be introduced into the Eurpean market place. The company is currently working also on the FDA regulatory process, expecting a Breakthrough Device Designation, which ensure an expedited regulatory process towards FDA approval.
About Our Team
Creator: Max Ostermeier
Location: Niedersachsen
Bio: Max G. Ostermeier (MBA), is a medical device serial entrepreneur and founder and CEO of Implandata Ophthalmic Products GmbH, which is the leader in digital transformation in the management of chronic eye diseases. Prior to that Max was CEO and founder of Cranium Telemetrics GmbH, a start-up which has developed the first implantable intracranial pressure sensor for better management of hydrocephalus patients. He also founded and managed Odicrain GmbH, a medical device company with a portable device for early detection of critical brain injuries. For both companies, a successful exit was accomplished with US based companies.
By self-monitoring of their disease, glaucoma patients will be empowered and informed about their disease state, their therapeutic response and motivated to increased therapy adherence. This will ensure better disease outcome and peace of mind, resulting in preservation of eye sight and quality of life.
96% of the patients using our EYEMATE system would also recommend it to other patients.
How We Help Physicians
Eye care specialists will attain real-time, real-life information about the disease status, the therapeutic response and the therapy compliance of their patients. Data is remotely gathered under normal-life conditions and delivered to the eye doctor. By this the eye doctor can provide precision medicine and personalized treatment to their patients. Patient management can performed remotely, limiting the number of necessary office visits. By more efficient, digitally enabled patient management, eye doctors can provide better care to a higher number of patients.
How We Help Hospitals
Important disease parameters are gathered at a higher quantity and quality outside the eye centers. Number of patients visits can be reduced to really medically necessary visits. Patients can be managed more efficiently via the EYEMATE digital system and resources dedicated to patient according to their real need.
How We Help Partners
Implandata's EYEMATE system can benefit partners, which are especially engaged in providing therapies to glaucoma patients, as the EYEMATE system is a data-centric therapy guidance system allowing personalized medicine and treatment of glaucoma therapies.
Payers would benefit by more efficient and effective use of resources and slower or stopped disease progression, by which patients can be kept for a longer period in less costly early disease state.
Innovation Details
Intellectual Property Summary
Implandata owns 15 granted or pendind patent famiies and has extensive know and trade secrets.
See patent portfolio under: https://worldwide.espacenet.com/searchResults?ST=singleline&locale=de_EP&submitted=true&DB=&query=implandata+ophthalmic+products
The EYEMATE system has been extensively tested in human, demonstrating safety, utility and efficacy.
See full list of literature under: https://infocenter.my-eyemate.com/publications.html
Regulatory Status
Implandata will submit for a Breakthrough Device Designation, which ensure an expedited regulatory approval process and with FDA approval CMS reimbursement for a period of 4 years. Implandata is very confident to attain Breakthrough Device Designation by early 2021.
How we will use the funds raised
- Execution of FDA regulatoy process
- Execution of reimbursement strategy
- Advancing pipeline of next generation technologies and products
- Focused market lauch for market validation
Thank You
The most exciting theme in our work is to help patients at threat of vision loss to better understand and manage their disease. The EYEMATE protects glaucoma patients vision and their quality of life. Patients will be empowered by self-monitoring and eye care specialists enabled to provide more efficacious therapies to their patients. And the healthcare system will benefit by more efficient use of resources and better care for patients with the chronic eye disease glaucoma.
Investor Info
Market Size
An external analysis by PwC revealed a market potential for the EYEMATE system of up to 1 billion Euro/USD per year.
Today there are close to 80 million patients with glaucoma worldwide. Because of growing and aging populations, we will have close to 120 million patients in 2040.
Projected 3 Year Growth
In three years, the company will be acquired by one of the larger and global players in the ophthalmic industry. The founders and investors are working towards this goal, by spending resources in the most critical and valuable activities to accomplish this goal.
Revenue Model
Implandata's business model is based on two components:
- Moderate one-time payment for the enabling devices
- Sustainable long-term revenues on a data provision subscription model
With expected Breakthrough Device Designation and FDA approval, Implandata's product will be covered by CMS for 4 years. Within this 4 years, the company will be able to establish extensive HEOR data to justify non-provisional long-term reimbursement.
Competitors
Implandata is the first company, offering remote monitoring and care of glaucoma patients via a proprietary mobile data collection and AI-backed digital platform and user interface. Implandata's EYEMATE system is CE marked. Competitors are still working on getting ready for clinical studies in order to start the regulatory approval process.
Implandata is seen as the clear technology leader in this area. Together with the first market mover advantage, Implandata will be able to establish itself as the leading company for remote glaucoma care. Based on this platform, Implandata may enter into other chronic eye disease indications, like macular degeneration or diabetic retinophaty, which are also diseases where patients are at risk to irreversibly lose eyesight.
Traction
Implandata has established certified user centers in Germany, Switzerland and the UK and will continue a focused market validation by the end of the year 2020.
Due Diligence Docs
Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.
Help us find best new ideas to fund by telling us what you think. Your feedback goes
straight to the team behind this project in private, so tell them what you really think.
Max G. Ostermeier (MBA), is a medical device serial entrepreneur and founder and CEO of Implandata Ophthalmic Products GmbH, which is the leader in digital...
